Antoni Bayes-Genis1, James L Januzzi2, Hanna K Gaggin2, Marta de Antonio3, Shweta R Motiwala2, Elisabet Zamora3, Amparo Galán4, Mar Domingo5, Agustín Urrutia3, Josep Lupón3. 1. Heart Failure Unit, Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain. Electronic address: abayesgenis@gmail.com. 2. Cardiology Division, Medicine Department, Massachusetts General Hospital, Boston, Massachusetts, USA. 3. Heart Failure Unit, Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain. 4. Biochemistry Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 5. Heart Failure Unit, Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Abstract
BACKGROUND: Soluble ST2 is involved in multiple pathogenic pathways, including cardiac strain, inflammation, and myocardial necrosis with remodeling. The relative weight of ST2 and the point at which its prognostic value in heart failure (HF) is affected by different degrees of myocardial strain, inflammation, necrosis, and remodeling is unknown. METHODS AND RESULTS: We examined whether soluble ST2 levels improves HF risk stratification relative to other biomarkers representative of multiple pathogenic pathways-N-terminal pro-B-type natriuretic peptide (NT-proBNP; strain), high-sensitivity C-reactive protein (hsCRP; inflammation), and galectin-3 and high-sensitivity troponin T (hsTnT; necrosis and remodeling)-in 1,015 patients with mean left ventricular ejection fraction (LVEF) 33.5%. Mean follow-up was 4.2 ± 2.1 years. The correlation with soluble ST2 was highest with NT-proBNP (r = 0.32; P < .001) and lowest with galectin-3 (r = 0.15; P < .001). ST2 levels increased with increasing concentrations of the other biomarkers (P < .001 in all cases). During follow-up, 467 patients died. Soluble ST2 remained an independent prognosticator of risk at every tertile of each biomarker. This was observed even after adjusting for clinical parameters. CONCLUSIONS: Soluble ST2 may be regarded as a 3-in-1 prognosis biomarker in HF. ST2 provides valuable long-term risk stratification information in HF beyond that reported by other biomarkers of stretch, inflammation, necrosis, and remodeling.
BACKGROUND: Soluble ST2 is involved in multiple pathogenic pathways, including cardiac strain, inflammation, and myocardial necrosis with remodeling. The relative weight of ST2 and the point at which its prognostic value in heart failure (HF) is affected by different degrees of myocardial strain, inflammation, necrosis, and remodeling is unknown. METHODS AND RESULTS: We examined whether soluble ST2 levels improves HF risk stratification relative to other biomarkers representative of multiple pathogenic pathways-N-terminal pro-B-type natriuretic peptide (NT-proBNP; strain), high-sensitivity C-reactive protein (hsCRP; inflammation), and galectin-3 and high-sensitivity troponin T (hsTnT; necrosis and remodeling)-in 1,015 patients with mean left ventricular ejection fraction (LVEF) 33.5%. Mean follow-up was 4.2 ± 2.1 years. The correlation with soluble ST2 was highest with NT-proBNP (r = 0.32; P < .001) and lowest with galectin-3 (r = 0.15; P < .001). ST2 levels increased with increasing concentrations of the other biomarkers (P < .001 in all cases). During follow-up, 467 patients died. Soluble ST2 remained an independent prognosticator of risk at every tertile of each biomarker. This was observed even after adjusting for clinical parameters. CONCLUSIONS: Soluble ST2 may be regarded as a 3-in-1 prognosis biomarker in HF. ST2 provides valuable long-term risk stratification information in HF beyond that reported by other biomarkers of stretch, inflammation, necrosis, and remodeling.
Authors: Emma Roca; Lexa Nescolarde; Josep Lupón; Jaume Barallat; James L Januzzi; Peter Liu; M Cruz Pastor; Antoni Bayes-Genis Journal: J Cardiovasc Transl Res Date: 2017-04-05 Impact factor: 4.132
Authors: Andrew Cai; Alejandra Miyazawa; Nicholas Sunderland; Susan E Piper; Thomas G J Gibbs; Duolao Wang; Sadie Redding; George Amin-Youseff; Olaf Wendler; Jonathan Byrne; Philip A MacCarthy; Ajay M Shah; Theresa A McDonagh; Rafał Dworakowski Journal: Cardiol J Date: 2019-06-21 Impact factor: 2.737
Authors: Santiago Roura; Carolina Gálvez-Montón; David de Gonzalo-Calvo; Ana Gámez Valero; Paloma Gastelurrutia; Elena Revuelta-López; Cristina Prat-Vidal; Carolina Soler-Botija; Aida Llucià-Valldeperas; Isaac Perea-Gil; Oriol Iborra-Egea; Francesc E Borràs; Josep Lupón; Vicenta Llorente-Cortés; Antoni Bayes-Genis Journal: J Cell Mol Med Date: 2017-05-29 Impact factor: 5.310
Authors: Cristina Pacho; Mar Domingo; Raquel Núñez; Josep Lupón; Julio Núñez; Jaume Barallat; Pedro Moliner; Marta de Antonio; Javier Santesmases; Germán Cediel; Santiago Roura; M Cruz Pastor; Jordi Tor; Antoni Bayes-Genis Journal: BMC Geriatr Date: 2018-05-09 Impact factor: 3.921